Atossa Therapeutics, Inc. has announced its financial results for the third quarter ended September 30, 2026. The announcement, made on November 10, 2026, is significant as it provides insights into the company's operational performance and strategic direction.
Company Overview
Atossa Therapeutics, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol ATOS. Based in Seattle, Washington, Atossa focuses on developing innovative therapies for breast cancer and other conditions.
What the Filing Says
In the recent filing, Atossa stated, "On November 10, 2026, Atossa Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026 and providing a Company update." The press release is included as Exhibit 99.1 in the filing.
Impact
This financial update may affect various stakeholders, including investors, analysts, and competitors in the pharmaceutical preparations industry. As Atossa continues to navigate its market position, the results could influence investor sentiment and competitive strategies within the sector.
What's Next
The filing does not specify what happens next for Atossa Therapeutics, leaving stakeholders to anticipate further developments following this financial disclosure.
Financial Highlights
While specific financial figures were not disclosed in the filing, Atossa Therapeutics, Inc. highlighted its ongoing commitment to advancing its pipeline of therapies. The company continues to focus on innovative treatment options for breast cancer, which remains a core aspect of its business strategy.
Company Background
Founded as Atossa Genetics Inc. in 2010, the company underwent a name change to Atossa Therapeutics, Inc. in 2010, reflecting its broadened focus on therapeutic developments. The company is incorporated in Delaware and operates out of Seattle, Washington.
Contact Information
For further inquiries, stakeholders can reach Atossa Therapeutics at their business address: 1448 NW Market Street, Suite 500, Seattle, WA 98107, or by phone at (206) 588-0256.
Additional Information
The filing does not provide detailed financial results, such as revenue figures, net income, or cash flow statements, which are typically included in a quarterly earnings report. Stakeholders may need to refer to the attached press release for comprehensive financial data.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










